China
/
Pharma
/
SZSE:000999

China Resources Sanjiu Medical & Pharmaceutical Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Simply Wall St

March 15, 2025

China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Full Year 2024 Results

Key Financial Results

Revenue: CN¥27.6b (up 12% from FY 2023).
Net income: CN¥3.37b (up 18% from FY 2023).
Profit margin: 12% (in line with FY 2023).
EPS: CN¥2.63 (up from CN¥2.23 in FY 2023).

earnings-and-revenue-growth — SZSE:000999 Earnings and Revenue Growth March 15th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

China Resources Sanjiu Medical & Pharmaceutical Revenues Beat Expectations

Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Valuation

Our analysis of these results suggests China Resources Sanjiu Medical & Pharmaceutical may be undervalued based on 6 important criteria we look at. Click here to view our comprehensive analysis and gain insights into the stock's investment prospects.

If you're looking to trade China Resources Sanjiu Medical & Pharmaceutical, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.